Original Article
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
N Engl J Med 2009; 361:1651-1661October 22, 2009
- Abstract
Background
Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease.
Methods
Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel–Haenszel procedure used to estimate odds ratios across centers.
Results
All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non–Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non–Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations.
Conclusions
Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Media in This Article
Figure 1
Odds Ratios for GBA Mutations among Patients, as Compared with Controls, at Each Study Center and Overall.Figure 2
Distributions of Mutations among Study Patients of Ashkenazi Jewish Ancestry and Those of Non–Ashkenazi Jewish Ancestry.Article Activity
- Article
Several lines of evidence suggest an association between parkinsonism and mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GBA), which is deficient in patients with Gaucher's disease. In this rare mendelian disorder, lysosomal accumulation of glucocerebroside results in a broad spectrum of disease manifestations including hepatosplenomegaly, anemia, thrombocytopenia, bone disease, and, at times, neurologic involvement.1,2 Multiple independent studies have reported an increased frequency of GBA mutations in various cohorts of patients with parkinsonism.3-21 However, several genomewide association studies have not identified this locus, and the degree of association has remained somewhat unclear, as many studies were not large enough to unequivocally label GBA mutations as risk alleles associated with Parkinson's disease.
Recognition of the association between GBA mutations and parkinsonism began in the clinic, with the identification of rare patients with Gaucher's disease who also had parkinsonian symptoms. Clinical descriptions appeared as case reports,22,23 larger series of patients24,25 and prospective studies.26 Pedigree analyses revealed that relatives of patients with Gaucher's disease, many of whom were obligate heterozygotes, had an increased incidence of Parkinson's disease.27,28
Almost 300 GBA mutations have been identified in patients with Gaucher's disease, including missense, nonsense, and frameshift mutations as well as insertions, deletions, and complex alleles.29 Various expression studies have shown that many of these mutations result in a significant loss of glucocerebrosidase activity.30 The GBA gene, located on 1q21–22, includes 11 exons and has a similar pseudogene 16 kb downstream. The 85-kb region surrounding GBA is particularly gene-rich, encompassing seven genes and two pseudogenes.31 Recombination within and around the GBA locus occurs relatively frequently,32 complicating genotype analyses.
The frequency and distribution of GBA mutations vary among populations. Among Ashkenazi Jews, for whom the carrier frequency is between 1 person in 12 and 1 in 16,1,6 one common mutation, N370S, accounts for approximately 70% of mutant alleles.1 In other ethnic groups, the carrier frequency is usually less than 1%, and the associated mutations are more diverse. Although N370S is also common in European populations and is exclusively associated with non-neuronopathic Gaucher's disease, it has not been encountered among Asians.33 A second relatively frequent and panethnic mutation associated with neuronopathic Gaucher's disease is L444P, which can be a point mutation or part of a complex allele encompassing a portion of the pseudogene sequence.32
This international collaborative study of GBA mutations in patients with Parkinson's disease was undertaken to better ascertain the frequency of GBA mutations by pooling data for individual persons from 16 centers, representing 4 continents, including 5691 patients and 4898 controls. Findings based on the data from 13 of the 16 centers (4185 of the case patients and 3597 of the controls) have been published previously.5-16,19 Our goals were to establish the combined frequency of GBA mutations among sites, to explore the range of GBA mutations encountered, and to identify clinical features shared among GBA mutation carriers.
Methods
Study Subjects and Procedures
Researchers known to be genotyping cohorts of patients with Parkinson's disease for GBA mutations were solicited for this collaboration. Sixteen centers participated, and data were collected and analyzed at the National Human Genome Research Institute (NHGRI), Bethesda, Maryland (Table 1Table 1
Baseline Data for the Study Groups, According to Center.). The subjects were from a total of 16 centers: 4 in North America, 1 in South America, 3 in Asia, 2 in Israel, and 6 in Europe. Ethnicity was self-reported. Ashkenazi Jews provided the country of origin of their grandparents. Written informed consent was obtained from all subjects under the supervision of each local ethics committee. All patients fulfilled the clinical diagnostic criteria for Parkinson's disease of the U.K. Parkinson's Brain Bank.34 Because the detection methods and number of mutations that could be identified varied greatly from center to center, 12 standard DNA samples from patients with Gaucher's disease were genotyped by each center, and the results were analyzed at the NHGRI. All centers could reliably detect mutations N370S and L444P, unless the mutant allele included large stretches of the GBA pseudogene sequence. Some centers could identify three to eight specific selected point mutations (Table 1). In addition, five centers sequenced all the exons of GBA, and a sixth sequenced exons for a subgroup of subjects. Thus, results evaluating two mutations (N370S and L444P), six to eight mutations, and the entire coding sequence were analyzed separately (see Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). Two frequent GBA variants, E326K and T369M, were evaluated but not included as mutant alleles.
The extent of clinical data collected from each site varied (Table 1). Some study centers provided only the age, family history, sex, ethnic group, and diagnosis of each subject, whereas others reported more complete data, including symptoms at presentation, age at disease onset, specific clinical manifestations, response to medications, and standardized scores on the Hoehn and Yahr staging system, the Unified Parkinson's Disease Rating Scale, or both. Only one proband was studied per family, and patients with diagnoses other than Parkinson's disease were excluded.
Controls were screened for signs or symptoms of parkinsonism, and centers attempted to match controls and patients with regard to age, sex, and ethnic group. Controls with a family history of Parkinson's disease were removed because of their increased risk of having parkinsonism ultimately develop.
Study Design
The a priori aim in this study was to conduct a combined analysis of risk associated with GBA mutations from various centers. Our analyses used patient-level data from both published and unpublished studies. We assessed associations between Parkinson's disease and GBA mutations in not only all available genotyped samples, but also in distinct subgroups of the total population (see the Supplementary Appendix for detailed analyses of subgroups).
Statistical Analysis
Descriptive statistics were calculated for each study center. Available data on family history of Parkinson's disease and seven clinical features of Parkinson's disease (asymmetric onset, bradykinesia, cognitive changes, orthostatic hypotension, postural instability, resting tremor, and rigidity) were analyzed. Clinical features were compared between case patients carrying GBA mutations and those without mutations, means were compared with the use of a two-tailed Student's t-test, and frequency differences were compared between patients with and those without GBA mutations by means of the chi-square test.
We first estimated the odds ratios for mutations in GBA across cohorts. To accomplish this, we conducted fixed-effects Mantel–Haenszel analyses using all available case patients and controls from each study center. These models calculate crude odds ratios and confidence intervals from counts of mutations in case patients and controls in each study and then combine the odds ratios from study-specific two-by-two tables into a summary measure. Three Mantel–Haenszel analyses were performed, using any mutation, N370S, and L444P as the separate independent variables. No multiple-test correction was used in our analyses.
The heterogeneity of effects in the Mantel–Haenszel analyses were evaluated using Woolf's test for heterogeneity.35 Analyses of the possible interactions contributing to the heterogeneity of odds ratios were limited by the data available for analysis, so several additional Mantel–Haenszel analyses were carried out. First, we excluded data from Japan and Norway, both together and independently, on the basis of the assumption that general genetic homogeneity in these samples could be compounded by the active recruitment of family members of case patients, influencing the independence (or in the Norwegian cohort, the nonindependence) of differences in mutation frequency between case patients and controls. An additional analysis, performed by omitting data from Tel Aviv, Israel — the center with the most robust odds ratio with respect to the standard error of the estimate — confirmed that these data were not inflating the combined odds ratio.
To follow up on the results from the Mantel–Haenszel analyses, multivariate logistic-regression models were used to examine the association between GBA mutations and Parkinson's disease in subgroups stratified on the basis of the level of sequencing coverage and Ashkenazi Jewish or non–Ashkenazi Jewish ethnicity. These stratified models combined data for subjects across studies, including all subjects with complete data for covariates of self-reported ethnic group, age at the time of sampling, and sex. For regression modeling and covariate descriptions, data for 702 patients and 570 controls were excluded because age, sex, or ethnic group was unknown. Identical parameters were used in logistic-regression models testing the association of Parkinson's disease with variants E326K and T369M. Chi-square tests of heterogeneity were used to compare effect-size differences between models stratifying Ashkenazi Jewish and non–Ashkenazi Jewish ethnicity assessing the risks attributable to all GBA mutations and N370S and L444P only, across all levels of sequencing coverage. Detailed results and a description of these regression models are given in the Supplementary Appendix.
All data analyses were conducted with the use of R software (version 2.8.0).36 Source code for plotting of the meta-analysis results is available in the software package “r.meta” (available from http://cran.cnr.berkeley.edu).
Results
Genotyping was performed for a total of 5691 patients with Parkinson's disease: 780 Ashkenazi Jewish patients and 4911 patients with no known Ashkenazi Jewish ancestry. The 4898 controls for whom genotyping was performed included 387 Ashkenazi Jewish persons and 4511 from other ethnic groups. Table 1 lists the frequency of mutations and baseline characteristics of cohorts at each center. Full sequencing was performed on DNA samples obtained from 2060 patients and 1677 controls.
Figure 1Figure 1
Odds Ratios for GBA Mutations among Patients, as Compared with Controls, at Each Study Center and Overall. shows the odds ratios for mutations in patients versus controls, standard errors, and confidence limits from the Mantel–Haenszel procedure performed on data from each independent study center; the odds were also combined across the centers. Data from four centers were excluded in this analysis, because individual controls were not provided (Haifa, Israel) or mutations were not found among the controls (Brazil, Singapore, and Tübingen, Germany).Results from the analysis of any GBA mutation as an independent variable (Figure 1A) show that each center had an overrepresentation of mutations among patients as compared with controls, although the confidence intervals varied considerably. Eight centers had odds ratios greater than 5. The overall combined odds ratio shows how greatly the confidence interval is reduced when data from the individual centers are combined. Individual odds ratios for the GBA point mutations L444P and N370S are also shown (Figure 1B and 1C, respectively). Although the odds ratios for each mutation are overwhelmingly positive, they were higher for L444P.
Combined odds ratios from Mantel–Haenszel analyses were homogeneous for L444P and N370S (P=0.35 and P=0.50, respectively, by Woolf's test for heterogeneity). This finding allows for confidence in reporting the Mantel–Haenszel combined odds ratios for N370S (odds ratio, 3.96; 95% confidence interval [CI], 2.60 to 6.02) and L444P (odds ratio, 6.73; 95% CI, 4.50 to 15.42). However, the Mantel–Haenszel odds ratio for any GBA mutation was significantly heterogeneous (P=0.02 by Woolf's test for heterogeneity). After excluding data from Japan and Norway, the odds ratio was slightly attenuated (5.43; 95% CI, 3.89 to 7.57), but the heterogeneity was no longer significant (P=0.41 by Woolf's test for heterogeneity), and further excluding the Tel Aviv data resulted in a homogeneous odds ratio (P=0.34 by Woolf's test for heterogeneity) of 5.30 (95% CI, 3.59 to 7.94). Independent exclusions of data from either Norway or Japan resulted in homogeneous odds ratios (Japan data excluded: odds ratio, 4.91; 95% CI, 3.60 to 6.70; P=0.14 by Woolf's test for heterogeneity; Norway data excluded: odds ratio, 6.35, 95% CI, 4.60 to 8.75; P=0.10 by Woolf's test for heterogeneity) (Figure 1D). Thus, we can confidently report a Mantel–Haenszel odds ratio of 5.43 for GBA mutations, in patients versus controls, even when these centers are excluded.
Overall, when screening solely for N370S and L444P, one of these two mutations was found in 15% of Ashkenazi Jewish patients as compared with 3% of Ashkenazi Jewish controls and in 3% of non–Ashkenazi Jewish patients as compared with less than 1% of non–Ashkenazi Jewish controls. However, the frequency of N370S in Ashkenazi Jewish patients differed among the centers. N370S was not seen in any Asian patients or controls.
All Ashkenazi Jewish subjects were screened for the presence or absence of six to eight different GBA mutations (Table 1). Including this larger number of screened mutations (rather than just L444P and N370S) increased the odds ratio for any mutation, among patients as compared with controls, to 6.48 (95% CI, 3.78 to 11.09). The distribution of specific GBA mutations among Ashkenazi Jewish patients with Parkinson's disease, of whom approximately 20% carried a GBA mutation, is shown in Figure 2AFigure 2
Distributions of Mutations among Study Patients of Ashkenazi Jewish Ancestry and Those of Non–Ashkenazi Jewish Ancestry.. Approximately 20% of the identified mutant alleles were neither L444P nor N370S. Among the non–Ashkenazi Jewish subjects, the entire GBA coding region was sequenced in 1883 patients and 1611 controls; the odds ratio for any GBA mutation was 6.51 (95% CI, 3.62 to 11.74). The distribution of mutations identified among non–Ashkenazi Jewish patients (Figure 2B) indicates that as many as 45% of mutant alleles could be missed if focusing solely on N370S and L444P. Moreover, 20 of 43 non–Ashkenazi Jewish patients who had complete sequence data and had L444P carried other pseudogene changes and hence had recombinant alleles.The full-sequencing data identified two common GBA variants, E326K and T369M, which are not pathogenic in patients with Gaucher's disease.37 Neither mutation had a significant association with Parkinson's disease (see the Supplementary Appendix).
Seventeen patients (13 of whom were Ashkenazi Jews) carried two GBA mutations. Thirteen of these patients had the N370S/N370S genotype, two had the N370S/R496H genotype, one had the N370S/V394L genotype, and one had the N370S/L444P genotype.
Age at onset was found to be significantly lower among patients with GBA mutations as compared with those without mutations (P<0.001), with a mean age of 54.9 years and 58.8 years, respectively. The mean period from diagnosis to evaluation was 7.8 years in both groups.
Information about a family history of parkinsonism was available for 4401 of the patients studied. In all, 18% of patients without GBA mutations reported having a first- or second-degree relative with Parkinson's disease, as compared with 24% of patients with a GBA mutation (P=0.006).
The frequencies of seven clinical findings associated with Parkinson's disease in patients with GBA mutations and those without mutations are shown in Figure 3Figure 3
Clinical Manifestations of Parkinson's Disease in Study Patients with a GBA Mutation and Those without a Mutation.. In general, the symptom profile for the two groups was similar, although mutations were associated with a significantly lower frequency of asymmetric onset (P<0.001), bradykinesia (P<0.001), resting tremor (P=0.03), and rigidity (P<0.001). There was no significant difference between the two groups in the frequency of orthostatic hypotension (P=0.26) or postural instability (P=0.12). Among the 1948 patients for whom the presence or absence of cognitive changes was recorded, changes were reported for 26% of patients with mutations and 19% of those without (P=0.007).Discussion
The results of our analysis indicate that there is an association between GBA mutations and Parkinson's disease. The combined data show that this finding is not exclusive to a specific ethnic group or a specific GBA mutation. Although mutations in GBA are most likely a susceptibility factor rather than a mendelian cause of Parkinson's disease, the high frequency of mutations among ethnically diverse, heterogeneous cohorts of patients with Parkinson's disease makes the mutations in this gene the most common genetic risk factor for Parkinson's disease that have been identified to date.
The major limitation of this study was the unavoidable differences in data-ascertainment methods among the study centers. Moreover, some sites were more successful than others in matching case patients and controls with regard to age and sex. To ensure that the analysis was not driven by a small subgroup of centers, we evaluated the variance in odds ratios across centers. Excluding the center with the most precise estimate (Tel Aviv) and the centers with the most extreme odds ratios (Norway and Japan) resulted in only a slight attenuation of the combined odds ratio for any GBA mutation among patients as compared with controls, which in all analyses remained 5.43 or higher.
This study confirms the need to sequence all exons to accurately ascertain the frequency of GBA mutations among both patients and controls. The combined odds ratios may be underestimated, because so many of the centers performed limited mutation analyses. Our data show that among non–Ashkenazi Jewish patients, as many as 45% of mutant alleles can be missed when screening for only the N370S and L444P mutations. Furthermore, analysis of specific mutations may produce a serious bias. Among the 1883 non–Ashkenazi Jewish patients who had sequenced samples, GBA mutations were found in 7% (odds ratio vs. controls, 6.51), although only 35% of the samples included in our entire analysis were fully sequenced. An adequate sample size and accurate genotyping of control samples are imperative to avoid underestimating the frequencies of rare variants.
Despite the difficulty in determining the phenotypic profile associated with the GBA mutations found in this study, which intentionally included only patients that met diagnostic criteria for Parkinson's disease, some trends are apparent. As compared with patients who did not have a GBA mutation, those with a mutation presented on average 4 years earlier, were more likely to have a family history of Parkinson's disease, and had a lower incidence of bradykinesia and resting tremor and a higher incidence of cognitive changes, a trend supporting earlier reports.3,5,6,18,19,24,25 However, because of the exclusion criteria used in the analysis, our findings do not accurately reflect the full spectrum of parkinsonian symptoms associated with GBA mutations. An increased frequency of GBA mutations has also been described in cohorts with Lewy-body disorders,38-40 although not in multiple-system atrophy,41 and further studies are warranted.
Even though our data provide validation of GBA as a risk factor associated with Parkinson's disease, the ultimate challenge is to establish the mechanisms contributing to this association. Both a gain-of-function mechanism due to enhanced protein aggregation or lysosomal dysfunction42 and a loss of function related to fluctuations in levels of ceramide43 have been postulated. Further research to elucidate the pathophysiology of both Gaucher's disease and Parkinson's disease will facilitate more accurate genetic counseling and lead to the development of new therapeutic strategies.
Supported in part by the Intramural Research Programs of NHGRI and the National Institute on Aging (project Z01AG000957-05), National Institutes of Health; grants from the National Institute of Neurological Disorders and Stroke and the National Center for Research Resources (NS050487, NS060113, and NS40256); grants from the Parkinson's Disease Foundation; a Merit Review Award from the Department of Veterans Affairs, Seattle; a grant from the German National Genome Network, German Ministry for Education and Research (01GS08134); a grant from the French Parkinson's Disease Genetics Study Group; a grant from the Duke–National University of Singapore (NUS) Graduate Medical School, National Medical Research Council, Biomedical Research Council, Singapore Millennium Foundation; a grant from SingHealth, Singapore General Hospital, National Neuroscience Institute; the Tel Aviv Sourasky Medical Center Grant of Excellence; grants from the Wolfson and Kahn Foundations; a grant from the Portuguese Fundação para a Ciência e a Tecnologia; a grant from the National Science Council, Executive Yuan, Taiwan (NSC-95-2314-B-182A-061); and a Grant-in-Aid for Scientific Research on Priority Areas, Applied Genomics, and Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Dr. Berg reports receiving lecture fees from UCB, GlaxoSmithKline, Teva, and Lundbeck, advisory fees from Novartis, UCB, GlaxoSmithKline, and Teva, and grant support from Janssen Pharmaceuticals and Teva Pharma; Dr. Fahn, receiving lecture fees from Boehringer Ingelheim and consulting fees from Anteres Pharma, Boehringer Ingelheim, Elsai, EMD Serono, Genzyme, Impax Pharmaceuticals, Intec Pharma, Kyowa, Novartis, Teva, Valeant, and Vernalis and serving on the Merz Pharma Data and Safety Monitoring Board; Dr. Farrer, holding a provisional patent for RNA interference as a treatment for neurodegenerative disease and a patent for LRRK2 mutations and receiving research support from Lundbeck and Isis Pharmaceuticals and lecture fees from Genzyme and GlaxoSmithKline; Dr. Gasser, receiving research support from Novartis, consulting fees from Cephalon Pharma and Merck Serono, and lecture fees from Boehringer Ingelheim, Merck Serono, Novartis, and Schwarz Pharma and holding a patent for the detection of LRRK2 mutations; Dr. Griffith, receiving consulting fees from Teva and lecture fees from Teva and Novartis; Dr. Lang, receiving advisory fees from Biovail, Boehringer Ingelheim, Cephalon, Ceregene, Eisai, Medtronic, Lundbeck, NeuroMolecular, Novartis, Solvay, Taro, and Teva, speaker's fees or other support from GlaxoSmithKline and UCB, and grant support from Taro; Dr. Ottman, receiving consulting fees from Ortho-McNeil Janssen Scientific Affairs and holding equity in Trigeminal Solutions; Dr. Perera, receiving grant support from Genzyme of Brazil; and Dr. Rozenberg, receiving grant support form Genzyme of Brazil. No other potential conflict of interest relevant to this article was reported.
We thank John Hardy, Ph.D. (from the Institute of Neurology, Queen's Square, London) for helpful discussion; Dora Yearout for technical assistance; John W. Roberts, M.D., for recruitment of subjects at the University of Washington, Seattle; Jae Choi and Julia Fekecs for preparation of drafts of the figures and Chunhui Yu for developing the online survey (all from NHGRI); Neil Oden (from Emmes, Rockville, MD) for statistical assistance; and T. Lumley for maintenance of source codes in R software.
Source Information
The authors' full names, degrees, and affiliations are listed in the Appendix.
Address reprint requests to Dr. Sidransky at the Section on Molecular Neurogenetics, National Human Genome Research Institute, Rm. 1A213, 35 Convent Dr., Bethesda, MD 20892-3708, or at sidranse@mail.nih.gov.
Appendix
The full names of the authors, and their degrees, are as follows: Ellen Sidransky, M.D., Michael A. Nalls, Ph.D., Jan O. Aasly, M.D., Ph.D., Judith Aharon-Peretz, M.D., Grazia Annesi, Ph.D., Egberto R. Barbosa, M.D., Anat Bar-Shira, Ph.D., Daniela Berg, M.D., Jose Bras, M.S., Alexis Brice, M.D., Chiung-Mei Chen, M.D., Ph.D., Lorraine N. Clark, Ph.D., Christel Condroyer, B.S., Elvira V. De Marco, Ph.D., Alexandra Dürr, M.D., Ph.D., Michael J. Eblan, B.A., Stanley Fahn, M.D., Matthew J. Farrer, Ph.D., Hon-Chung Fung, M.D., Ph.D., Ziv Gan-Or, B.Med.Sci., Thomas Gasser, M.D., Ruth Gershoni-Baruch, M.D., Nir Giladi, M.D., Alida Griffith, M.D., Tanya Gurevich, M.D., Cristina Januario, M.D., Peter Kropp, Ph.D., Anthony E. Lang, M.D., Guey-Jen Lee-Chen, Ph.D., Suzanne Lesage, Ph.D., Karen Marder, M.D., M.P.H., Ignacio F. Mata, Ph.D., Anat Mirelman, Ph.D., Jun Mitsui, M.D., Ikuko Mizuta, M.D., Ph.D., Giuseppe Nicoletti, M.D., Catarina Oliveira, M.D., Ph.D., Ruth Ottman, Ph.D., Avi Orr-Urtreger, M.D., Ph.D., Lygia V. Pereira, Ph.D., Aldo Quattrone, M.D., Ekaterina Rogaeva, Ph.D., Arndt Rolfs, M.D., Hanna Rosenbaum, M.D., Roberto Rozenberg, Ph.D., Ali Samii, M.D., Ted Samaddar, B.S., Claudia Schulte, Dip.Biol., Manu Sharma, Ph.D., Andrew Singleton, Ph.D., Mariana Spitz, M.D., Eng-King Tan, M.D., Nahid Tayebi, Ph.D., Tatsushi Toda, M.D., Ph.D., André R. Troiano, M.D., Shoji Tsuji, M.D., Ph.D., Matthias Wittstock, M.D., Tyra G. Wolfsberg, Ph.D., Yih-Ru Wu, M.D., Cyrus P. Zabetian, M.D., Yi Zhao, M.D., Ph.D., and Shira G. Ziegler, B.A.
The authors' affiliations are as follows: the Section on Molecular Neurogenetics, Medical Genetics Branch, NHGRI (E.S., M.J.E., T.S., N.T., S.G.Z.), the Laboratory of Neurogenetics, National Institute on Aging (M.A.N., J.B., A.S.), and the Genome Technology Branch, National Human Genome Research Institute (T.G.W.) — all at the National Institutes of Health, Bethesda, MD; the Department of Neurology, St. Olav's Hospital, and the Department of Neuroscience, Norwegian University of Science and Technology — both in Trondheim, Norway (J.O.A.); the Cognitive Neurology and Movement Disorder Unit (J.A.-P.), the Human Genetics Rambam Medical Center (R.G.-B.), the Bruce Rappaport Faculty of Medicine (R.G.-B.), and the Departments of Hematology and Bone Marrow Transplantation, Technion, Israel Institute of Technology (H.R.) — all in Haifa, Israel; the Institute of Neurological Sciences, National Research Council, Cosenza (G.A., E.V.D.M., G.N., A.Q.), and the Institute of Neurology, Department of Medical Sciences, University Magna Graecia, Catanzaro (G.N., A.Q.) — both in Italy; the Movement Disorders Unit, Neurology Department, University of São Paulo Medical School (E.R.B., M.S.), and the Molecular Genetics Lab, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo (L.V.P., R.R.) — both in São Paulo; the Genetic Institute (A.B.-S., Z.G.-O., A.O.-U.), the Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center (N.G., T. Gurevich, A.M.), and the Sackler Faculty of Medicine, Tel-Aviv University (Z.G.-O., N.G., T.G., A.O.-U.) — all in Tel Aviv, Israel; the Hertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany (D.B., T. Gasser, C.S., M.S.); the Center for Neuroscience and Cell Biology, University of Coimbra (J.B., C.O.), and the Neurology Service, University of Coimbra Hospital (C.J., C.O.) — both in Coimbra, Portugal; INSERM, Centre de Recherche de l'Institut du Cerveau et de la Moëlle Épinière Unité Mixte de Recherche_S975 (formerly Unité Mixte de Recherche_S679), Pierre et Marie Curie University (A.B., C.C., A.D., S.L., A.T.), Assistance Publique–Hôpitaux de Paris, and the Department of Genetics and Cytogenetics, Pitié–Salpêtrière Hospital (A.B., A.D.) — all in Paris; the Department of Neurology, Chang Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan (C.-M.C., H.-C.F., Y.-R.W.); the Taub Institute for Research on Alzheimer's Disease and the Aging Brain (L.N.C., K.M.), the Center for Human Genetics (L.N.C.), the Departments of Pathology (L.N.C.), Neurology (S.F., K.M., R.O.), and Psychiatry (K.M.), and the Gertrude H. Sergievsky Center (K.M., R.O.), Columbia University College of Physicians and Surgeons; and the Department of Epidemiology, Mailman School of Public Health, Columbia University and New York State Psychiatric Institute (R.O.) — all in New York; the Laboratories of Neurogenetics, Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL (M.J.F.); Booth Gardner Parkinson's Care Center, Evergreen Hospital Medical Center, Kirkland, WA (A.G.); the Institute for Medical Psychology (P.K.), the Albrecht-Kossel-Institute for Neuroregeneration (A.R.), and the Department of Neurology (M.W.), University of Rostock, Rostock, Germany; the Department of Medicine, Division of Neurology, Movement Disorders Centre, Toronto Western Hospital (A.E.L.), and the Centre for Research in Neurodegenerative Diseases, Tanz Neuroscience Building, University of Toronto (E.R.) — both in Toronto; the Department of Life Science, National Taiwan Normal University, Taipei, Taiwan (G.-J.L.-C.); the Parkinson's Disease and Geriatric Research Education and Clinical Centers, VA Puget Sound Health Care System, and Department of Neurology, University of Washington — both in Seattle (I.F.M., A.S., C.P.Z.); the Department of Neurology, University of Tokyo Graduate School of Medicine, Tokyo (J.M., S.T.), and the Division of Neurology and Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe (I.M., T.T.) — both in Japan; and Singapore General Hospital, National Neuroscience Institute (E.-K.T., Y.Z.), and Duke–NUS Graduate Medical School (E.-K.T.) — both in Singapore.
- References
References
1
Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AR, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:3635-68.
2
Sidransky E . Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 2004;83:6-15
CrossRef | Web of Science | Medline3
Lwin A ,Orvisky E ,Goker-Alpan O ,LaMarca ME ,Sidransky E . Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81:70-73
CrossRef | Web of Science | Medline4
Aharon-Peretz J ,Rosenbaum H ,Gershoni-Baruch R . Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972-1977
Full Text | Web of Science | Medline5
Clark LN ,Ross BM ,Wang Y , et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007;69:1270-1277
CrossRef | Web of Science | Medline6
Gan-Or Z ,Giladi N ,Rozovski U , et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283
CrossRef | Web of Science | Medline7
Sato C ,Morgan A ,Lang AE , et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005;20:367-370
CrossRef | Web of Science | Medline8
Eblan MJ ,Nguyen J ,Ziegler SG , et al. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 2006;21:282-283
CrossRef | Web of Science | Medline9
Spitz M ,Rozenberg R ,Pereira Lda V ,Reis Barbosa E . Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord 2008;14:58-62
CrossRef | Web of Science | Medline10
Bras J ,Paisan-Ruiz C ,Guerreiro R , et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 2009;30:1515-1517
CrossRef | Web of Science | Medline11
Mata IF ,Samii A ,Schneer SH , et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008;65:379-382
CrossRef | Web of Science | Medline12
Toft M ,Pielsticker L ,Ross OA ,Aasly JO ,Farrer MJ . Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 2006;66:415-417
CrossRef | Web of Science | Medline13
De Marco EV ,Annesi G ,Tarantino P , et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord 2008;23:460-463
CrossRef | Web of Science | Medline14
Ziegler SG ,Eblan MJ ,Gutti U , et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 2007;91:195-200
CrossRef | Web of Science | Medline15
Wu YR ,Chen CM ,Chao CY , et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007;78:977-979
CrossRef | Web of Science | Medline16
Tan EK ,Tong J ,Fook-Chong S , et al. Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 2007;64:1056-1058
CrossRef | Web of Science | Medline17
Neumann J ,Bras J ,Deas E , et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132:1783-1794
CrossRef | Web of Science | Medline18
Nichols WC ,Pankratz N ,Marek DK , et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72:310-316
CrossRef | Web of Science | Medline19
Mitsui J ,Mizuta I ,Toyoda A , et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009;66:571-576
CrossRef | Web of Science | Medline20
Kalinderi K ,Bostantjopoulou S ,Paisan-Ruiz C ,Katsarou Z ,Hardy J ,Fidani L . Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 2009;452:87-89
CrossRef | Web of Science | Medline21
The PDGene Database. Alzheimer research forum, 2009. (Accessed September 25, 2009, at http://www.pdgene.org/.)
22
Machaczka M ,Rucinska M ,Skotnicki AB ,Jurczak W . Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999;61:216-217
CrossRef | Web of Science | Medline23
Tayebi N ,Callahan M ,Madike V , et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-321
CrossRef | Web of Science | Medline24
Neudorfer O ,Giladi N ,Elstein D , et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89:691-694
Medline25
Tayebi N ,Walker J ,Stubblefield B , et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003;79:104-109
CrossRef | Web of Science | Medline26
Goker-Alpan O ,Lopez G ,Vithayathil J ,Davis J ,Hallett M ,Sidransky E . The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008;65:1353-1357
CrossRef | Web of Science | Medline27
Goker-Alpan O ,Schiffmann R ,LaMarca ME ,Nussbaum RL ,McInerney-Leo A ,Sidransky E . Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940
CrossRef | Web of Science | Medline28
Halperin A ,Elstein D ,Zimran A . Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006;36:426-428
CrossRef | Web of Science | Medline29
Hruska KS ,LaMarca ME ,Scott CR ,Sidransky E . Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008;29:567-583
CrossRef | Web of Science | Medline30
Montfort M ,Chabas A ,Vilageliu L ,Grinberg D . Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and “modifier” polymorphisms. Hum Mutat 2004;23:567-575[Erratum, Hum Mutat 2005;26:276.]
CrossRef | Web of Science | Medline31
Winfield SL ,Tayebi N ,Martin BM ,Ginns EI ,Sidransky E . Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 1997;7:1020-1026
Web of Science | Medline32
Tayebi N ,Stubblefield BK ,Park JK , et al. Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. Am J Hum Genet 2003;72:519-534
CrossRef | Web of Science | Medline33
Wan L ,Hsu CM ,Tsai CH ,Lee CC ,Hwu WL ,Tsai FJ . Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol Dis 2006;36:422-425
CrossRef | Web of Science | Medline34
Gibb WR ,Lees AJ . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752
CrossRef | Web of Science | Medline35
Woolf B . On estimating the relation between blood group and disease. Ann Hum Genet 1955;19:251-253
CrossRef | Medline36
R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2005. (Accessed September 25, 2009, at http://www.R-project.org.)
37
Park JK ,Tayebi N ,Stubblefield BK , et al. The E326K mutation and Gaucher disease: mutation or polymorphism? Clin Genet 2002;61:32-34
CrossRef | Web of Science | Medline38
Goker-Alpan O ,Giasson BI ,Eblan MJ , et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67:908-910
CrossRef | Web of Science | Medline39
Clark LN ,Kartsaklis LA ,Wolf Gilbert R , et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009;66:578-583
CrossRef | Web of Science | Medline40
Farrer MJ ,Williams LN ,Algom AA , et al. Glucosidase-beta variations and Lewy body disorders. Parkinsonism Relat Disord 2009;15:414-416
CrossRef | Web of Science | Medline41
Segarane B ,Li A ,Paudel R , et al. Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 2009;72:1185-1186
CrossRef | Web of Science | Medline42
DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E. The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord 2009 May 7 (Epub ahead of print).
43
Bras J ,Singleton A ,Cookson MR ,Hardy J . Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 2008;275:5767-5773
CrossRef | Web of Science | Medline
- Citing Articles (112)
Citing Articles
1
Michael J. Hurley, David T. Dexter. (2012) Voltage-gated calcium channels and Parkinson's disease. Pharmacology & Therapeutics 133:3, 324-333
CrossRef2
Bram Meeus, Aline Verstraeten, David Crosiers, Sebastiaan Engelborghs, Marleen Van den Broeck, Maria Mattheijssens, Karin Peeters, Ellen Corsmit, Ellen Elinck, Barbara Pickut, Rik Vandenberghe, Patrick Cras, Peter Paul De Deyn, Christine Van Broeckhoven, Jessie Theuns. (2012) DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiology of Aging 33:3, 629.e5-629.e18
CrossRef3
M. Siebert, K.C. Donis, M. Socal, C.R.M. Rieder, V.E. Emmel, F. Vairo, K. Michelin-Tirelli, M. França, A.C. D’Abreu, C. Bettencourt, M. Lima, I. Lopes Cendes, M.L. Saraiva-Pereira, L.B. Jardim. (2012) Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3. Parkinsonism & Related Disorders 18:2, 185-190
CrossRef4
Jonathan C. Goldsmith, Vence L. Bonham, Clinton H. Joiner, Gregory J. Kato, Allan S. Noonan, Martin H. Steinberg. (2012) Framing the research agenda for sickle cell trait: Building on the current understanding of clinical events and their potential implications. American Journal of Hematologyn/a-n/a
CrossRef5
Nobutaka Hattori. (2012) Autosomal dominant Parkinsonism: its etiologies and differential diagnoses. Parkinsonism & Related Disorders 18, S1-S3
CrossRef6
Enza Maria Valente, Giuseppe Arena, Liliana Torosantucci, Vania Gelmetti. (2012) Molecular pathways in sporadic PD. Parkinsonism & Related Disorders 18, S71-S73
CrossRef7
Helen Michelakakis, Georgia Xiromerisiou, Efthimios Dardiotis, Maria Bozi, Demetrios Vassilatis, Persa-Maria Kountra, Gianna Patramani, Marina Moraitou, Dimitra Papadimitriou, Eleftherios Stamboulis, Leonidas Stefanis, Elias Zintzaras, Georgios M. Hadjigeorgiou. (2012) Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. Movement Disordersn/a-n/a
CrossRef8
M. Maral Mouradian. (2012) MicroRNAs in Parkinson's disease. Neurobiology of Disease
CrossRef9
Suzanne Lesage, Alexis Brice. (2012) Role of Mendelian genes in “sporadic” Parkinson's disease. Parkinsonism & Related Disorders 18, S66-S70
CrossRef10
Benjamin Liou, Gregory A. Grabowski. (2011) Is E326K glucocerebrosidase a polymorphic or pathological variant?. Molecular Genetics and Metabolism
CrossRef11
Michael A. van Es, Helenius J. Schelhaas, Paul W. J. van Vught, Nicola Ticozzi, Peter M. Andersen, Ewout J. N. Groen, Claudia Schulte, Hylke M. Blauw, Max Koppers, Frank P. Diekstra, Katsumi Fumoto, Ashley Lyn LeClerc, Pamela Keagle, Bastiaan R. Bloem, Hans Scheffer, Bart F. L. van Nuenen, Marka van Blitterswijk, Wouter van Rheenen, Anne-Marie Wills, Patrick P. Lowe, Guo-fu Hu, Wenhao Yu, Hiroko Kishikawa, David Wu, Rebecca D. Folkerth, Claudio Mariani, Stefano Goldwurm, Gianni Pezzoli, Philip Van Damme, Robin Lemmens, Caroline Dahlberg, Anna Birve, Rubén Fernández-Santiago, Stefan Waibel, Christine Klein, Markus Weber, Anneke J. van der Kooi, Marianne de Visser, Dagmar Verbaan, Jacobus J. van Hilten, Peter Heutink, Eric A. M. Hennekam, Edwin Cuppen, Daniela Berg, Robert H. Brown, Vincenzo Silani, Thomas Gasser, Albert C. Ludolph, Wim Robberecht, Roel A. Ophoff, Jan H. Veldink, R. Jeroen Pasterkamp, Paul I. W. de Bakker, John E. Landers, Bart P. van de Warrenburg, Leonard H. van den Berg. (2011) Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology 70:6, 964-973
CrossRef12
Claire Henchcliffe, Richard Dodel, M. Flint Beal. (2011) Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology 95:4, 601-613
CrossRef13
O. A. Buneeva, A. E. Medvedev. (2011) Mitochondrial dysfunction in Parkinson’s disease. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 5:4, 313-336
CrossRef14
Yanick J. Crow. (2011) Lupus: How much “complexity” is really (just) genetic heterogeneity?. Arthritis & Rheumatism 63:12, 3661-3664
CrossRef15
B García-Rodríguez, P Alfonso, M Mallén, M Pocoví, P Giraldo. (2011) Gaucher disease: a pyrosequencing frequency analysis of the N370S and L444P mutations in the Spanish population. Clinical Geneticsno-no
CrossRef16
Ziv Gan-Or, Anat Bar-Shira, Tanya Gurevich, Nir Giladi, Avi Orr-Urtreger. (2011) Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. neurogenetics 12:4, 325-332
CrossRef17
Nir Giladi, Anat Mirelman, Avner Thaler, Anat Bar-Shira, Tanya Gurevich, Avi Orr-Urtreger. (2011) Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease. Journal of the Neurological Sciences 310:1-2, 17-20
CrossRef18
A. Singleton, J. Hardy. (2011) A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Human Molecular Genetics 20:R2, R158-R162
CrossRef19
G. K. Tofaris, H. T. Kim, R. Hourez, J.-W. Jung, K. P. Kim, A. L. Goldberg. (2011) Ubiquitin ligase Nedd4 promotes -synuclein degradation by the endosomal-lysosomal pathway. Proceedings of the National Academy of Sciences 108:41, 17004-17009
CrossRef20
Karin Wirdefeldt, Margaret Gatz, Chandra A. Reynolds, Carol A. Prescott, Nancy L. Pedersen. (2011) Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiology of Aging 32:10, 1923.e1-1923.e8
CrossRef21
C.-L. Huang, Y.-H. Wu-Chou, S.-C. Lai, H.-C. Chang, T.-H. Yeh, Y.-H. Weng, R.-S. Chen, Y.-Z. Huang, C.-S. Lu. (2011) Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson’s disease in Taiwan. European Journal of Neurology 18:10, 1227-1232
CrossRef22
Susan Duty, Peter Jenner. (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology 164:4, 1357-1391
CrossRef23
David Crosiers, Jessie Theuns, Patrick Cras, Christine Van Broeckhoven. (2011) Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy 42:2, 131-141
CrossRef24
Maria Xilouri, Leonidas Stefanis. (2011) Autophagic pathways in Parkinson disease and related disorders. Expert Reviews in Molecular Medicine 13,
CrossRef25
Andrew B Singleton. (2011) Exome sequencing: a transformative technology. The Lancet Neurology 10:10, 942-946
CrossRef26
I. Ferrer, I. López-Gonzalez, M. Carmona, E. Dalfó, A. Pujol, A. Martínez. (2011) Neurochemistry and the non-motor aspects of PD. Neurobiology of Disease
CrossRef27
Coro Paisán-Ruiz, Laura Parkkinen, Tamas Revesz. 2011. Lewy Bodies in Conditions other than Disorders of α-Synuclein. , 238-241.
CrossRef28
Kurt A. Jellinger. 2011. Parkinson's Disease. , 194-223.
CrossRef29
Marina Moraitou, Georgios Hadjigeorgiou, Ioannis Monopolis, Efthimios Dardiotis, Maria Bozi, Demitris Vassilatis, Lluisa Vilageliu, Daniel Grinberg, Georgia Xiromerisiou, Leonidas Stefanis, Helen Michelakakis. (2011) β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Molecular Genetics and Metabolism 104:1-2, 149-152
CrossRef30
Mia Horowitz, Metsada Pasmanik-Chor, Idit Ron, Edwin H. Kolodny. (2011) The enigma of the E326K mutation in acid β-glucocerebrosidase. Molecular Genetics and Metabolism 104:1-2, 35-38
CrossRef31
Rose-Marie Javier, Pascal Guggenbuhl. (2011) Maladie de Gaucher : diagnostic, suivi et traitement. Revue du Rhumatisme Monographies 78:4, 246-253
CrossRef32
Jae Hyuk Choi, Barbara Stubblefield, Mark R. Cookson, Ehud Goldin, Arash Velayati, Nahid Tayebi, Ellen Sidransky. (2011) Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Molecular Genetics and Metabolism 104:1-2, 185-188
CrossRef33
Naomi Seki, Yuji Takahashi, Hiroyuki Tomiyama, Ekaterina Rogaeva, Shigeo Murayama, Yoshikuni Mizuno, Nobutaka Hattori, Connie Marras, Anthony E Lang, Peter St George-Hyslop, Jun Goto, Shoji Tsuji. (2011) Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. Journal of Human Genetics 56:9, 671-675
CrossRef34
José Luis Capablo Liesa, Alicia Sáez de Cabezón, Raquel Alarcia Alejos, José Ramón Ara Callizo. (2011) Características clínicas de las formas neurológicas de la enfermedad de Gaucher. Medicina Clínica 137, 6-11
CrossRef35
James R. Lupski, John W. Belmont, Eric Boerwinkle, Richard A. Gibbs. (2011) Clan Genomics and the Complex Architecture of Human Disease. Cell 147:1, 32-43
CrossRef36
Wendy Westbroek, Ann Marie Gustafson, Ellen Sidransky. (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends in Molecular Medicine 17:9, 485-493
CrossRef37
Atul Mehta. (2011) Gaucher's disease: the changing paradigm of a lysosomal disorder. Medicina Clínica 137, 3-5
CrossRef38
Chiung-Mei Chen, Chih-Hsin Lin, Hsueh-Fen Juan, Fen-Ju Hu, Ya-Chin Hsiao, Hsin-Yi Chang, Chih-Ying Chao, I-Cheng Chen, Li-Ching Lee, Tsu-Wei Wang, Ya-Tang Chen, Yi-Tsun Chen, Guey-Jen Lee-Chen, Yih-Ru Wu. (2011) ATP13A2 variability in Taiwanese Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 156:6, 720-729
CrossRef39
Christine Klein, Rosalind Chuang, Connie Marras, Anthony E. Lang. (2011) The curious case of phenocopies in families with genetic Parkinson's disease. Movement Disorders 26:10, 1793-1802
CrossRef40
Glenda M. Halliday, Janice L. Holton, Tamas Revesz, Dennis W. Dickson. (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica 122:2, 187-204
CrossRef41
Tamar Shachar, Christophe Lo Bianco, Alessandra Recchia, Christoph Wiessner, Annick Raas-Rothschild, Anthony H. Futerman. (2011) Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Movement Disorders 26:9, 1593-1604
CrossRef42
Paul M. A. Antony, Nico J. Diederich, Rudi Balling. (2011) Parkinson’s disease mouse models in translational research. Mammalian Genome 22:7-8, 401-419
CrossRef43
David S. Gross, Ronald L. Klein, Stephan N. Witt. 2011. Therapeutics: Harnessing the Power of Molecular and Pharmacological Chaperones. , 385-421.
CrossRef44
S. P. Sardi, J. Clarke, C. Kinnecom, T. J. Tamsett, L. Li, L. M. Stanek, M. A. Passini, G. A. Grabowski, M. G. Schlossmacher, R. L. Sidman, S. H. Cheng, L. S. Shihabuddin. (2011) CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences 108:29, 12101-12106
CrossRef45
T. M. Dawson, V. L. Dawson. (2011) A Lysosomal Lair for a Pathogenic Protein Pair. Science Translational Medicine 3:91, 91ps28-91ps28
CrossRef46
Alexander Zimprich, Anna Benet-Pagès, Walter Struhal, Elisabeth Graf, Sebastian H. Eck, Marc N. Offman, Dietrich Haubenberger, Sabine Spielberger, Eva C. Schulte, Peter Lichtner, Shaila C. Rossle, Norman Klopp, Elisabeth Wolf, Klaus Seppi, Walter Pirker, Stefan Presslauer, Brit Mollenhauer, Regina Katzenschlager, Thomas Foki, Christoph Hotzy, Eva Reinthaler, Ashot Harutyunyan, Robert Kralovics, Annette Peters, Fritz Zimprich, Thomas Brücke, Werner Poewe, Eduard Auff, Claudia Trenkwalder, Burkhard Rost, Gerhard Ransmayr, Juliane Winkelmann, Thomas Meitinger, Tim M. Strom. (2011) A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. The American Journal of Human Genetics 89:1, 168-175
CrossRef47
Joseph R. Mazzulli, You-Hai Xu, Ying Sun, Adam L. Knight, Pamela J. McLean, Guy A. Caldwell, Ellen Sidransky, Gregory A. Grabowski, Dimitri Krainc. (2011) Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell 146:1, 37-52
CrossRef48
Philip M. Boone, Wojciech Wiszniewski, James R. Lupski. (2011) Genomic medicine and neurological disease. Human Genetics 130:1, 103-121
CrossRef49
Guanghua Wu, Xuenan Wang, Xungang Feng, Aimei Zhang, Jifeng Li, Kejin Gu, Jian Huang, Shuchao Pang, Haixin Dong, Huijie Gao, Bo Yan. (2011) Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease. Brain Research 1394, 105-111
CrossRef50
Pilar Giraldo, Jose Luis Capablo, Pilar Alfonso, Beatriz Garcia-Rodriguez, Paz Latre, Pilar Irun, Alicia Saenz Cabezon, Miguel Pocovi. (2011) Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?. Journal of Inherited Metabolic Disease 34:3, 781-787
CrossRef51
Juan M Benito, José M García Fernández, Carmen Ortiz Mellet. (2011) Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opinion on Therapeutic Patents 21:6, 885-903
CrossRef52
Valerie Cullen, S. Pablo Sardi, Juliana Ng, You-Hai Xu, Ying Sun, Julianna J. Tomlinson, Piotr Kolodziej, Ilana Kahn, Paul Saftig, John Woulfe, Jean-Christophe Rochet, Marcie A. Glicksman, Seng H. Cheng, Gregory A. Grabowski, Lamya S. Shihabuddin, Michael G. Schlossmacher. (2011) Acid β-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α-synuclein processing. Annals of Neurology 69:6, 940-953
CrossRef53
Lars Bertram. (2011) Alzheimer’s Genetics in the GWAS Era: A Continuing Story of ‘Replications and Refutations’. Current Neurology and Neuroscience Reports 11:3, 246-253
CrossRef54
Karin Wirdefeldt, Hans-Olov Adami, Philip Cole, Dimitrios Trichopoulos, Jack Mandel. (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. European Journal of Epidemiology 26:S1, 1-58
CrossRef55
Anthony H. V. Schapira. (2011) Aetiopathogenesis of Parkinson’s disease. Journal of Neurology 258:S2, 307-310
CrossRef56
Thomas Gasser, John Hardy, Yoshikuni Mizuno. (2011) Milestones in PD genetics. Movement Disorders 26:6, 1042-1048
CrossRef57
C. Warren Olanow, K. McNaught. (2011) Parkinson's disease, proteins, and prions: Milestones. Movement Disorders 26:6, 1056-1071
CrossRef58
Hiroyuki Tomiyama, Hiroyo Yoshino, Kotaro Ogaki, Lin Li, Chikara Yamashita, Yuanzhe Li, Manabu Funayama, Ryogen Sasaki, Yasumasa Kokubo, Shigeki Kuzuhara, Nobutaka Hattori. (2011) PLA2G6 variant in Parkinson's disease. Journal of Human Genetics 56:5, 401-403
CrossRef59
Wassilios G. Meissner, Mark Frasier, Thomas Gasser, Christopher G. Goetz, Andres Lozano, Paola Piccini, José A. Obeso, Olivier Rascol, Anthony Schapira, Valerie Voon, David M. Weiner, François Tison, Erwan Bezard. (2011) Priorities in Parkinson's disease research. Nature Reviews Drug Discovery 10:5, 377-393
CrossRef60
Jung-Mi Choi, Jung-Hoon Hong, Min-Joo Chae, Ngyuen Phuoc Hung, Hyun-Sook Kang, Hyeo-Il Ma, Yun Joong Kim. (2011) Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease. Neuroscience Letters 493:3, 97-101
CrossRef61
T. Farfel-Becker, E. B. Vitner, S. N. R. Pressey, R. Eilam, J. D. Cooper, A. H. Futerman. (2011) Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Human Molecular Genetics 20:7, 1375-1386
CrossRef62
E. K. Tan, A. H. Schapira. (2011) New LRRK2 variants identified in Parkinson’s disease. European Journal of Neurology 18:3, 369-370
CrossRef63
A. H. V. Schapira. (2011) Challenges to the development of disease-modifying therapies in Parkinson’s disease. European Journal of Neurology 18, 16-21
CrossRef64
Joshua M. Shulman, Philip L. De Jager, Mel B. Feany. (2011) Parkinson's Disease: Genetics and Pathogenesis. Annual Review of Pathology: Mechanisms of Disease 6:1, 193-222
CrossRef65
Lucio Santoro, Guido J. Breedveld, Fiore Manganelli, Rosa Iodice, Chiara Pisciotta, Maria Nolano, Francesca Punzo, Mario Quarantelli, Sabina Pappatà, Alessio Fonzo, Ben A. Oostra, Vincenzo Bonifati. (2011) Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. neurogenetics 12:1, 33-39
CrossRef66
(2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet 377:9766, 641-649
CrossRef67
Isidro Ferrer. (2011) Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease. Parkinson's Disease 2011, 1-13
CrossRef68
S. Lesage, M. Anheim, C. Condroyer, P. Pollak, F. Durif, C. Dupuits, F. Viallet, E. Lohmann, J.-C. Corvol, A. Honore, S. Rivaud, M. Vidailhet, A. Durr, A. Brice, , Y. Agid, A.- M. Bonnet, M. Borg, A. Brice, E. Broussolle, P. Damier, A. Destee, A. Durr, F. Durif, S. Lesage, E. Lohmann, M. Martinez, P. Pollak, O. Rascol, F. Tison, C. Tranchant, A. Troiano, M. Verin, F. Viallet, M. Vidailhet. (2011) Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Human Molecular Genetics 20:1, 202-210
CrossRef69
Gilbert J. Ho, Willie Liang, Masaaki Waragai, Kazunari Sekiyama, Eliezer Masliah, Makoto Hashimoto. (2011) Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders. International Journal of Alzheimer's Disease 2011, 1-18
CrossRef70
Barry Rosenbloom, Manisha Balwani, Jeff M. Bronstein, Edwin Kolodny, Swati Sathe, Andrea R. Gwosdow, John S. Taylor, J. Alexander Cole, Ari Zimran, Neal J. Weinreb. (2011) The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry. Blood Cells, Molecules, and Diseases 46:1, 95-102
CrossRef71
Monika Balzer-Geldsetzer, Ana Sofia Ferreira Braga da Costa, Martin Kronenbürger, Jörg B. Schulz, Sandra Röske, Annika Spottke, Ullrich Wüllner, Thomas Klockgether, Alexander Storch, Christine Schneider, Oliver Riedel, Hans-Ulrich Wittchen, Carola Seifried, Rüdiger Hilker, Nele Schmidt, Karsten Witt, Günther Deuschl, Brit Mollenhauer, Claudia Trenkwalder, Inga Liepelt-Scarfone, Susanne Gräber-Sultan, Daniela Berg, Thomas Gasser, Elke Kalbe, Maren Bodden, Wolfgang H. Oertel, Richard Dodel. (2011) Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK). Neuroepidemiology 37:3-4, 168-176
CrossRef72
Mun-Kyung Sunwoo, Seung-Min Kim, Sarah Lee, Phil Hyu Lee. (2011) Parkinsonism Associated with Glucocerebrosidase Mutation. Journal of Clinical Neurology 7:2, 99
CrossRef73
Xinmin Liu, Rong Cheng, Miguel Verbitsky, Sergey Kisselev, Andrew Browne, Helen Mejia-Sanatana, Elan D Louis, Lucien J Cote, Howard Andrews, Cheryl Waters, Blair Ford, Steven Frucht, Stanley Fahn, Karen Marder, Lorraine N Clark, Joseph H Lee. (2011) Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Medical Genetics 12:1, 104
CrossRef74
Kenya Nishioka, Owen A. Ross, Carles Vilariño-Güell, Stephanie A. Cobb, Jennifer M. Kachergus, David M.A. Mann, Julie Snowden, Anna M.T. Richardson, David Neary, Christopher A. Robinson, Alex Rajput, Spiridon Papapetropoulos, Deborah C. Mash, Rajesh Pahwa, Kelly E. Lyons, Zbigniew K. Wszolek, Dennis W. Dickson, Matthew J. Farrer. (2011) Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism & Related Disorders 17:1, 55-57
CrossRef75
Stanley Fahn, Joseph Jankovic, Mark Hallett. 2011. Current concepts on the etiology and pathogenesis of Parkinson disease. , 93-118.
CrossRef76
Soyeon Ahn. (2011) Introduction to bioinformatics: sequencing technology. Asia Pacific Allergy 1:2, 93
CrossRef77
Shoji TSUJI. (2011) Elucidation of Molecular Mechanisms of Neurological Diseases Based on Personal Genome Analyses. TRENDS IN THE SCIENCES 16:7, 84-92
CrossRef78
Núria Setó-Salvia, Javier Pagonabarraga, Henry Houlden, Berta Pascual-Sedano, Oriol Dols-Icardo, Arianna Tucci, Coro Paisán-Ruiz, Antonia Campolongo, Sofía Antón-Aguirre, Inés Martín, Laia Muñoz, Enric Bufill, Lluïsa Vilageliu, Daniel Grinberg, Mónica Cozar, Rafael Blesa, Alberto Lleó, John Hardy, Jaime Kulisevsky, Jordi Clarimón. (2011) Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Movement Disordersn/a-n/a
CrossRef79
Sophie E. Winder-Rhodes, Pablo Garcia-Reitböck, Maria Ban, Jonathan R. Evans, Thomas S. Jacques, Anu Kemppinen, Thomas Foltynie, Caroline H. Williams-Gray, Patrick F. Chinnery, Gavin Hudson, David J. Burn, Liesl M. Allcock, Stephen J. Sawcer, Roger A. Barker, Maria Grazia Spillantini. (2011) Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Movement Disordersn/a-n/a
CrossRef80
Stefan P. Schmid, Erwin D. Schleicher, Alexander Cegan, Christian Deuschle, Stephanie Baur, Ann-Kathrin Hauser, Matthis Synofzik, Karin Srulijes, Kathrin Brockmann, Daniela Berg, Walter Maetzler. (2011) Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. Movement Disordersn/a-n/a
CrossRef81
Arianna Tucci, Mike A Nalls, Henry Houlden, Tamas Revesz, Andrew B Singleton, Nicholas W Wood, John Hardy, Coro Paisán-Ruiz. (2010) Genetic variability at the PARK16 locus. European Journal of Human Genetics 18:12, 1356-1359
CrossRef82
Gregory M. Pastores. (2010) Neuropathic Gaucher disease. Wiener Medizinische Wochenschrift 160:23-24, 605-608
CrossRef83
F.-Y. Hu, J. Xi, J. Guo, L.-H. Yu, L. Liu, X.-H. He, Z.-L. Liu, X.-Y. Zou, Y.-M. Xu. (2010) Association of the glucocerebrosidase N370S allele with Parkinson’s disease in two separate Chinese Han populations of mainland China. European Journal of Neurology 17:12, 1476-1478
CrossRef84
Ehud Goldin. (2010) Gaucher disease and parkinsonism, a molecular link theory. Molecular Genetics and Metabolism 101:4, 307-310
CrossRef85
Kumar M Prakash, Eng-King Tan. (2010) Development of Parkinson’s disease biomarkers. Expert Review of Neurotherapeutics 10:12, 1811-1825
CrossRef86
Olaf A. Bodamer, Christina Hung. (2010) Laboratory and genetic evaluation of Gaucher disease. Wiener Medizinische Wochenschrift 160:23-24, 600-604
CrossRef87
Adriana Vaz dos Santos, Cristiane Pinheiro Pestana, Karen Rafaella da Silva Diniz, Mário Campos, Cláudia Bueno Abdalla-Carvalho, Ana Lúcia Zuma de Rosso, João Santos Pereira, Denise Hack Nicaretta, William Luciano de Carvalho, Jussara Mendonça dos Santos, Cíntia Barros Santos-Rebouças, Márcia Mattos Gonçalves Pimentel. (2010) Mutational analysis of GIGYF2, ATP13A2 and GBA genes in Brazilian patients with early-onset Parkinson's disease. Neuroscience Letters 485:2, 121-124
CrossRef88
John C. Morgan, Shyamal H. Mehta, Kapil D. Sethi. (2010) Biomarkers in Parkinson’s Disease. Current Neurology and Neuroscience Reports 10:6, 423-430
CrossRef89
Ozlem Goker-Alpan, Barbara K. Stubblefield, Benoit I. Giasson, Ellen Sidransky. (2010) Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathologica 120:5, 641-649
CrossRef90
Douglas B. Kell. (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology 84:11, 825-889
CrossRef91
John Hardy. (2010) Genetic Analysis of Pathways to Parkinson Disease. Neuron 68:2, 201-206
CrossRef92
Grisel Lopez, Ellen Sidransky. (2010) Autosomal recessive mutations in the development of Parkinson’s disease. Biomarkers in Medicine 4:5, 713-721
CrossRef93
I. Ron, D. Rapaport, M. Horowitz. (2010) Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Human Molecular Genetics 19:19, 3771-3781
CrossRef94
Andrew B. Singleton, John Hardy, Bryan J. Traynor, Henry Houlden. (2010) Towards a complete resolution of the genetic architecture of disease. Trends in Genetics 26:10, 438-442
CrossRef95
Jun Mitsui, Yoko Fukuda, Kyo Azuma, Hirokazu Tozaki, Hiroyuki Ishiura, Yuji Takahashi, Jun Goto, Shoji Tsuji. (2010) Multiplexed resequencing analysis to identify rare variants in pooled DNA with barcode indexing using next-generation sequencer. Journal of Human Genetics 55:7, 448-455
CrossRef96
Jose A Obeso, Maria C Rodriguez-Oroz, Christopher G Goetz, Concepcion Marin, Jeffrey H Kordower, Manuel Rodriguez, Etienne C Hirsch, Matthew Farrer, Anthony H V Schapira, Glenda Halliday. (2010) Missing pieces in the Parkinson's disease puzzle. Nature Medicine 16:6, 653-661
CrossRef97
Anthony H. V. Schapira, Eduardo Tolosa. (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nature Reviews Neurology 6:6, 309-317
CrossRef98
Krisztina K. Johansen, Linda R. White, Sigrid B. Sando, Jan O. Aasly. (2010) Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism & Related Disorders 16:5, 307-315
CrossRef99
Suzanne Lesage, Alexis Brice. 2010. Molecular Genetics of Parkinsonism. .
CrossRef100
Jae Hyuk Choi, Arash Velayati, Barbara K. Stubblefield, Avi Orr-Urtreger, Ziv Gan-Or, Nahid Tayebi, Ellen Sidransky. (2010) False-positive results using a Gaucher diagnostic kit – RecTL and N370S. Molecular Genetics and Metabolism 100:1, 100-102
CrossRef101
Kathrin Brockmann, Thomas Gasser. 2010. Genetic Basis of Monogenic Forms of Parkinson Disease. .
CrossRef102
S. Tsuji. (2010) Genetics of neurodegenerative diseases: insights from high-throughput resequencing. Human Molecular Genetics 19:R1, R65-R70
CrossRef103
Chiara Mencarelli, Mario Losen, Caroline Hammels, Jochen De Vry, Matthijs K. C. Hesselink, Harry W. M. Steinbusch, Marc H. De Baets, Pilar Martínez-Martínez. (2010) The ceramide transporter and the Goodpasture antigen binding protein: one protein - one function?. Journal of Neurochemistry
CrossRef104
Gilberto Bultron, Katherine Kacena, Daniel Pearson, Michael Boxer, Ruhua Yang, Swati Sathe, Gregory Pastores, Pramod K. Mistry. (2010) The risk of Parkinson’s disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease 33:2, 167-173
CrossRef105
Helen Latsoudis, Spyridon Papapetropoulos. (2010) Glucocerebrosidase as a genetic modifier influencing susceptibility and phenotype of Parkinson’s disease. Future Neurology 5:2, 189-193
CrossRef106
Vincenzo Bonifati. (2010) Shaking the genome: new studies reveal genetic risk for Parkinson's disease. The Lancet Neurology 9:2, 136-138
CrossRef107
Shoji Tsuji. (2010) Future directions of Neurology -Breakthrough to the next stage-. Rinsho Shinkeigaku 50:11, 771-777
CrossRef108
Changshui Xu, Jun Xu, Yanmin Zhang, Jianjun Ma, Hideshi Kawakami, Hirofumi Maruyama, Masaki Kamada. (2010) Analysis on the Susceptibility Genes in Two Chinese Pedigrees with Familial Parkinson's Disease. Neurology Research International 2010, 1-4
CrossRef109
Adam J. Harrington, Shusei Hamamichi, Guy A. Caldwell, Kim A. Caldwell. (2010) C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Developmental DynamicsNA-NA
CrossRef110
Sun Ju Chung. (2010) Genetics in Parkinson's disease. Journal of the Korean Medical Association 54:1, 70
CrossRef111
Anthony HV Schapira. (2010) Movement disorders: advances in cause and treatment. The Lancet Neurology 9:1, 6-7
CrossRef112
KURT SAMSON. (2009) International Study Confirms Glucocerebrosidase Mutations in Parkinson Disease. Neurology Today 9:23, 8
CrossRef
